Exciting early indications of a cure for Hepatitis C do not mean we should become complacent about the risks of contracting the debilitating disease, a leading Australian researcher warns.
Professor Geoff McCaughan, right, head of the Liver Immunobiology Program at Sydney’s Centenary Institute of medical research, says preliminary results of a newly developed oral treatment regime for liver transplant patients with Hepatitis C were showing promising results.
Professor Geoff McCaughan is at the frontier of liver transplantation.
The latest of a set of new therapies to treat hepatitis C virus (HCV) infections are so effective they could reduce the need for liver transplantation dramatically.
That’s the view of Professor Geoff McCaughan, Head of the Liver Injury and Cancer research program at the Centenary Institute, and Director of the Royal Prince Alfred Hospital’s liver transplant program. And he has put it forward in a deliberately speculative paper on the frontiers of liver transplantation released in the Journal of Hepatology, one of the world’s most important liver publications.
Professor Geoff McCaughan, Head of Centenary's Liver Immunobiology Group
The Therapeutic Goods Administration has approved the hepatitis C medication, Victrelis. There are about 217,000 Australians living with chronic hepatitis C. Victrelis has been found to be suitable for the treatment of 40 per cent of patients. Unlike hepatitis A and B, there is no vaccine, making better treatments more important.
The Head of the Centenary Institute’s liver unit, Professor Geoff McCaughan, says the approval is a major breakthrough for patients. Continue reading →